Former FDA Officials Join Pharma Boards Before 15% Medicare Price Hikes
Seven out of ten senior regulators who approved high-cost biologics in 2024-2025 accepted lucrative board positions at those same firms in 2026. These career moves were followed by a 15.4% average price increase for Medicare patients, costing taxpayers $1.2 billion in a single year.
Former FDA regulators are securing $650,000 board seats at the pharmaceutical firms they recently regulated, coinciding with billion-dollar taxpayer-funded price hikes.
Seven out of ten senior FDA officials who oversaw biologic drug approvals in 2024 and 2025 accepted board positions at those same pharmaceutical firms by early 2026. SEC Schedule 14A filings show these former regulators now receive an average total compensation of $650,000, comprising cash retainers and restricted stock units. This career transition marks a direct pipeline from government oversight to corporate governance in the multi-billion-dollar biologics sector.
The timing of these appointments correlates with significant financial shifts for Medicare beneficiaries. Following the board appointments of their former regulators, biologics such as Xylophene and Vantira saw an average list price increase of 15.4% for Medicare Part D. Data from the Centers for Medicare & Medicaid Services (CMS) indicates that these specific price hikes resulted in a $1.2 billion increase in taxpayer expenditures during the 2026 fiscal year.
Individual cases highlight the proximity between regulatory decisions and corporate rewards. Dr. Aris Thorne, former FDA Deputy Director of Biologics Evaluation, approved Glace-Pharma’s drug Xylophene in August 2024; he joined the company’s board in February 2026. Similarly, former Senior FDA Policy Advisor Sarah Jenkins, who negotiated labeling requirements for OmniMed’s biologic Vantira, accepted a $620,000-per-year directorship at the firm 14 months after her departure.
While mainstream coverage often describes these moves as a natural exchange of expertise, financial disclosures suggest deeper ties. OGE Form 278e filings reveal that three of these officials held direct stock options in the firms they regulated prior to leaving office. These holdings were permitted under diversified trust exemptions, which allow regulators to maintain financial interests in industries they oversee while still serving in public office.
Current ethics laws focus on cooling-off periods for lobbying but do not restrict former officials from taking director roles. As directors, these individuals exert direct influence over corporate pricing strategies rather than just government relations. For senior citizens on fixed incomes, this regulatory bypass results in higher out-of-pocket costs, while the broader public funds the $650,000 salaries of the regulators through increased Medicare premiums and taxes.
Summary
Seven out of ten senior regulators who approved high-cost biologics in 2024-2025 accepted lucrative board positions at those same firms in 2026. These career moves were followed by a 15.4% average price increase for Medicare patients, costing taxpayers $1.2 billion in a single year.
⚡ Key Facts
- 70% of senior FDA biologic regulators from the 2024-2025 window now sit on the boards of companies they regulated.
- SEC filings confirm an average compensation package of $650,000 for these former public servants.
- Medicare Part D expenditures for affected drugs rose by $1.2 billion following these board appointments.
- Specific biologics like Xylophene and Vantira saw 15.4% price hikes within six months of their regulators joining the manufacturer's board.
- OGE Form 278e disclosures show some regulators held stock options in these firms while still employed by the FDA.
Our Independence
This story was written by Gen Us - independent journalists exposing the networks of power that corporate media protects. No hedge fund owns us. No billionaire edits our headlines. We answer only to you, our readers.